Abstract
Among 107 renal cell carcinoma (RCC) patients with histopathologic subtype diagnosis who were treated at Albert Einstein Cancer Center with cytokines over a 10-year period, seven patients had sarcomatoid histology, 63 had clear cell carcinoma, and 10 patients had mixed histology (sarcomatoid and clear cell). Regardless of their histology, patients with a disease free interval of 2 years or more had significantly better survival. None of the patients with sarcomatoid histology responded to therapy. However, several patients with mixed and clear cell histology achieved partial or complete responses following high dose interleukin-2 (IL-2) therapy. The median survival of patients with sarcomatoid histology was the shortest (13.8 months), whilst that of patients with mixed and clear cell histology was much longer (34.8 months and 39.1 months, respectively). This result was statistically significant in both univariate and multivariate survival analysis (P<0.001 andP<0.01, respectively). Patients with mixed and clear cell histology had no significant difference in survival, and their median survival combined was significantly longer than that of patients with sarcomatoid histology (P<0.0001 in univariate analysis,P<0.01 in multivariate analysis). This study suggests that survival with a diagnosis of RCC is predicted by tumor histology and disease free interval, and this impacts on the ability to respond to standard therapy. Patients with mixed and clear cell histology respond to cytokine therapy. Other therapies should be sought for patients with sarcomatoid RCC.
Similar content being viewed by others
References
The Kidney. In: Cotran RS, Kumar V, Robbins SL, Schoen F (eds)Robbins Pathological Basis of Disease. Saunders: Philadelphia 1994; pp 927–990.
Belldegrun A, Abi-Ada AS, Figlin RA, de Kernion JB. Renal cell carcinoma: basic biology and current approaches to therapy.Seminar in Oncology 1991;18: 96–101.
Hawkins MJ. Immunotherapy with high dose interleukin 2. In: Vogelzang NJ, Scardino PT, Shipley WU, Coffey DS (eds).Comprehensive Textbook of Genitourinary Oncology Williams & Wilkins: Baltimore 1996;248–255.
Sparano JA, Dutcher JP, Wiernik PH. Low dose interleukin 2 for advanced renal cell carcinoma. In: Vogelzang NJ, Scardino PT, Shipley WU, Coffey DS (eds).Comprehensive Textbook of Genitourinary Oncology 1996; pp 256–276.
Elson PJ, Witte RS, Trump DL. Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma.Cancer 1988;48: 7310–7313.
Dutcher JPet al. Outpatient subcutaneous interleukin-2 and interferon alpha for metastatic renal cell cancer: five year follow-up of the Cytokine Working Group Study.The Cancer Journal from Scientific American 1996; 157–162.
Sella A, Logothetis CJ, Ro JY. Sarcomatoid renal cell carcinoma: a treatable entity.Cancer 1987;60: 1313–1316.
Tomera KN, Farrow GM, Lieber MM. Sarcomatoid Renal Carcinoma.The Journal of Urology 1983;130: 657–659.
Farrow GM, Harrison Jr EG, Utz DC. Sarcomas and sarcomatoid and mixed malignant tumors of the kidney in adult— Part III.Cancer 1968;22 556–563.
Ro JY, Ayala AG, Sella A, Samuels ML, Swanson DA. Sarcomatoid renal cell carcinoma: clinicopathologic. A study of 42 cases.Cancer 1987;59: 516–526.
Noguchi Set al.. Prognostic factors for metastatic renal cell cancer.Japanese Journal of Urology 1995;86: 1279–1286.
Gelb AB, Shibuya RB, Weiss LM, Medeiros LJ. Stage I renal cell carcinoma. A clinicopathologic study of 82 cases.American Journal of Surgical Pathology 1993;17: 275–286.
Steinberg P, Storkel S, Oesch F, Thoenes W. Carbohydrate metabolism in human renal clear cell carcinoma.Laboratory Investigations 1992;67: 506–511.
Ahn YS, Zerban H, Grobholz R, Bannasch P. Sequential changes in the glycogen content, expression of glucose transporters and enzymatic patterns during development of clear/acidophilic cell tumors in rat kidney.Carcinogenesis 1992;13: 2329–2334.
Kanamaru Het al.. Analysis of histological heterogeneity in renal cell carcinoma: tumor size related histological change and its prognostic significance.International Journal of Urology 1996;3: 256–260.
Fiori Eet al.. Renal cell carcinoma in adolescents. A case report and review of the literature.Panminerva medica 1996;38: 121–128.
Oleksowicz Let al. Interleukins in cancer therapy, rationale and current status.Clinical Immunotherapy 1994;1: 271–281.
Stenzl A, de Kernion JB. Pathology, biology and clinical staging of renal cell carcinoma.Seminars on Oncology 1989;16: 3–11.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Wu, J., Caliendo, G., Hu, XP. et al. Impact of histology on the treatment outcome of metastatic or recurrent renal cell carcinoma. Med Oncol 15, 44–49 (1998). https://doi.org/10.1007/BF02787344
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF02787344